Cytori Therapeutics Inc. (USA)  

(Public, NASDAQ:CYTX)   Watch this stock  
Find more results for CYTX
2.16
+0.03 (1.41%)
Jul 30 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 2.12 - 2.17
52 week 2.00 - 3.93
Open 2.17
Vol / Avg. 0.00/347,160.00
Mkt cap 162.99M
P/E     -
Div/yield     -
EPS -0.41
Shares 75.46M
Beta 2.24
Inst. own 19%
Jul 31, 2014
Cytori Therapeutics Inc Annual Shareholders Meeting - 12:00PM EDT - Add to calendar
Jun 4, 2014
Cytori Therapeutics at Jefferies Global Healthcare Conference
May 12, 2014
Q1 2014 Cytori Therapeutics Earnings Conference Call
May 12, 2014
Q1 2014 Cytori Therapeutics Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '14) 2013
Net profit margin -725.24% -214.64%
Operating margin -665.76% -257.35%
EBITD margin - -260.06%
Return on average assets -102.39% -61.37%
Return on average equity -1507.56% -546.09%
Employees 115 -
CDP Score - -

Address

3020 Callan Road
SAN DIEGO, CA 92121
United States - Map
+1-858-4580900 (Phone)
+1-858-4580994 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Cytori Therapeutics, Inc. develops cell therapies based on autologous adipose-derived stem and regenerative cells (ADRCs) to treat cardiovascular disease and repair soft tissue defects. The advanced therapeutic application in the Company's clinical pipeline is for cardiovascular disease. The Company�s products include Celbrush, Puregraft, and Cytori LipoBank. The Celbrush is available in the 10 milliliter and 3 milliliter sizes and is used in conjunction with a Soft-Ject Syringe in the corresponding size. The Puregraft System is developed for autologous fat grafting and aesthetic body contouring. The Puregraft System is available in two sizes: 250 milliliter, which processes 50-250 milliliter of tissue, and 850 milliliter, which processes 200-850 milliliter of tissue. The Cytori LipoBank is a GTP-compliant cryopreservation system that offers a long-term storage option for viable adipose tissue after a single liposuction.

Officers and directors

David M. Rickey Independent Chairman of the Board
Age: 58
Bio & Compensation  - Reuters
Marc H. Hedrick M.D. President, Chief Executive Officer, Director
Age: 51
Bio & Compensation  - Reuters
Mark E. Saad Chief Financial Officer
Age: 44
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Clyde W. Shores Executive Vice President - Marketing & Sales
Age: 54
Bio & Compensation  - Reuters
Steven Kesten M.D. Executive Vice President, Chief Medical Officer
Age: 55
Bio & Compensation  - Reuters
Lloyd H. Dean Independent Director
Age: 63
Bio & Compensation  - Reuters
Richard J. Hawkins Independent Director
Age: 65
Bio & Compensation  - Reuters
Paul W. Hawran CPA Independent Director
Age: 62
Bio & Compensation  - Reuters
E. Carmack Holmes M.D. Independent Director
Age: 76
Bio & Compensation  - Reuters
Gary A. Lyons Independent Director
Age: 63
Bio & Compensation  - Reuters